Expansion of Health Screening Pipeline to Contribute to Early Diagnosis of Gastric Cancer and Others 

Starting this year, Dow Biomedical has established a new 'Healthcare Division' not only to expand its existing diagnostic tests but also to enter the health screening market. The Healthcare Division has launched new health screening confirmation tests such as 'GastroPanel' and diversified immune tests like 'Freelite' specifically for screening purposes. These products are being introduced to medical institutions and screening centers as part of their marketing strategy. 

기사내용 일부 발췌

다우바이오메디카는 ▲현장검사(POCT) ▲면역검사(Immunology) ▲분자진단검사(Molecular) ▲건강검진 등 4개 파이프라인에서 다양한 검사 제품을 보유하고 있다. 현재 미국·영국·네덜란드·핀란드 등 글로벌 제조사 약 20곳과 제휴를 통해 상급종합병원을 포함한 국내 250곳에 달하는 병원·검사실·검진센터에 제품을 공급하고 있다.

특히 기존 시장에서 치열하게 경쟁하기보다는 다발골수종 진단 FLC 정량검사·위 건강 바이오마커 패널 검사 등 검사 제품을 발굴해 새로운 시장 수요를 창출하는 전략을 펼친다는 점에서 여타 수입사와 차별화된다.

“건강검진 파이프라인 확대로 위암 등 조기진단 기여”